Merck (MRK) Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. AAPL
2. BRZE
3. TTAN
4. CHYM
5. USO
6. COO
7. QCOM
8. IRT
9. AEO
10. MSI

Go back to Merck (MRK) Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
Merck & Co. (NYSE: MRK) Delayed: 147.53 -0.93 (0.63%)
Previous Close $148.46    52 Week High $65.46 
Open $148.96    52 Week Low $47.97 
Day High $149.41    P/E 100.36 
Day Low $147.18    EPS $1.47 
Volume 8,546,333